Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mckesson Corp. (MCK)
NYSE:MCK
Holding MCK?
Track your performance easily
Earnings Data
Report Date
Jan 29, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
$8.24Last Year’s EPS
$7.74Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 5.66%
|Next Earnings Date:Jan 29, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with significant revenue and EPS growth, enhanced shareholder returns, and strategic expansions in oncology and biopharma services. However, some concerns remain about the medical segment's performance and margin pressures from GLP-1 products.Company Guidance
In the earnings call for Q2 2025, McKesson provided detailed guidance and updates on its financial performance and strategic initiatives. The company reported a 21% increase in revenues, supported by the onboarding of a new strategic partner, with an underlying revenue growth of 8% excluding this partner. Adjusted operating profit grew by 7%, aligning with their long-term growth targets, and adjusted EPS saw a 13% increase. McKesson is targeting long-term adjusted EPS growth of 12% to 14%, aiming for 18% to 20% growth for the full fiscal year. The company highlighted the strength in its U.S. Pharmaceutical and Canadian businesses, along with significant contributions from its oncology and biopharma platforms. McKesson increased its full-year guidance for revenue and share repurchases, aiming to return $3.2 billion to shareholders. The company is focused on diversifying and strengthening its portfolio, emphasizing investments in digital, automation, and AI to enhance customer relationships and internal efficiencies.Strong Revenue Growth
Revenues grew 21%, with an 8% growth excluding the onboarding of a new strategic partner.
Adjusted EPS Growth
Adjusted EPS increased by 13%, driven by strong operating performance.
Shareholder Returns
Raised dividends by 15% and repurchased $4.3 billion in shares over the last 5 quarters.
Oncology Platform Expansion
Added 185 providers to the U.S. Oncology Network this fiscal year.
Biopharma Services Growth
Investments in automation and digital capabilities to drive better access, affordability, and adherence solutions.
Raised Full-Year Guidance
Increased adjusted operating profit outlook to 13% to 15% and EPS growth to 18% to 20%.
---
MCK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MCK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $548.69 | $606.82 | +10.59% |
| Aug 07, 2024 | $616.02 | $546.19 | -11.34% |
| May 07, 2024 | $543.84 | $541.71 | -0.39% |
| Feb 07, 2024 | $514.56 | $491.92 | -4.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mckesson Corp. (MCK) report earnings?
Mckesson Corp. (MCK) is schdueled to report earning on Jan 29, 2025, TBA Not Confirmed.
What is Mckesson Corp. (MCK) earnings time?
Mckesson Corp. (MCK) earnings time is at Jan 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MCK EPS forecast?
MCK EPS forecast for the fiscal quarter 2025 (Q3) is $8.24.
---